Drugs Containing Excipient (Inactive Ingredient) HISTIDINE HYDROCHLORIDE MONOHYDRATE

Generic drugs containing HISTIDINE HYDROCHLORIDE MONOHYDRATE excipient

Company	Ingredient	NDC	Excipient
ER Squibb & Sons LLC	nivolumab and hyaluronidase-nvhy	0003-6120	HISTIDINE HYDROCHLORIDE MONOHYDRATE
Merck Sharp & Dohme LLC	clesrovimab	0006-5073	HISTIDINE HYDROCHLORIDE MONOHYDRATE
Hikma Pharmaceuticals USA Inc	ustekinumab-hmny	0143-9168	HISTIDINE HYDROCHLORIDE MONOHYDRATE
Sanofi Vaccines US Inc	nirsevimab	49281-575	HISTIDINE HYDROCHLORIDE MONOHYDRATE
A-S Medication Solutions	ustekinumab-aekn	50090-7769	HISTIDINE HYDROCHLORIDE MONOHYDRATE
Genentech Inc	omalizumab	50242-040	HISTIDINE HYDROCHLORIDE MONOHYDRATE
Genentech Inc	obinutuzumab	50242-070	HISTIDINE HYDROCHLORIDE MONOHYDRATE

Histidine Hydrochloride Monohydrate Market Dynamics and Financial Trajectory

Last updated: September 2, 2026

Histidine hydrochloride monohydrate is a pharmaceutical-grade buffering excipient used mainly in biologics, vaccines, peptides, and other parenteral formulations. Its commercial outlook is tied to growth in injectable biologics rather than to independent pricing power. Demand should expand with antibody, peptide, and high-concentration subcutaneous products, while margins remain constrained by alternative buffers, relatively low use levels per dose, and qualification requirements.

Public companies do not generally report revenue, gross margin, or market share for histidine hydrochloride monohydrate as a standalone product. The market is therefore best assessed through biologics production, formulation development, supplier qualification, regulatory use, and capacity expansion.

What is histidine hydrochloride monohydrate used for in pharmaceutical formulations?

Histidine hydrochloride monohydrate is the hydrochloride salt of L-histidine containing one molecule of water of crystallization. It is used primarily as a buffer and pH-adjusting agent.

Attribute	Commercial relevance
Chemical identity	L-Histidine hydrochloride monohydrate
CAS number	5934-29-2
Primary function	Buffering and pH control
Main dosage forms	Injectable solutions, lyophilized biologics, peptide formulations, vaccines
Typical formulation role	Stabilization of proteins and control of pH during storage and administration
Principal end markets	Monoclonal antibodies, enzymes, recombinant proteins, vaccines, peptides, ADCs
Regulatory category	Pharmaceutical excipient, subject to product-specific quality and regulatory review
Primary purchasing criteria	Purity, endotoxin control, bioburden, elemental impurities, consistency, documentation, supply continuity

Histidine-based buffers are commonly selected for protein formulations because they can provide suitable buffering across a mildly acidic to near-neutral pH range. The choice depends on protein stability, aggregation behavior, chemical degradation, viscosity, container compatibility, and route of administration.

Histidine hydrochloride monohydrate may be used alone or with L-histidine, depending on the target pH and formulation design. It can also be combined with surfactants, sugars, polyols, amino acids, and stabilizing agents.

How large is the histidine hydrochloride monohydrate market?

A reliable standalone global revenue figure is not publicly established. Market reports often combine histidine hydrochloride with L-histidine, amino-acid excipients, laboratory reagents, or broader pharmaceutical buffer categories. Those groupings do not provide a defensible measure of pharmaceutical-grade histidine hydrochloride monohydrate revenue.

The addressable market has four characteristics:

1. It is a specialty excipient market rather than a large-volume commodity market.
2. Pharmaceutical demand is concentrated in biologics and injectable products.
3. Manufacturing demand is recurring but low per finished-dose unit.
4. Supplier value is driven more by quality systems and qualification than by the intrinsic cost of histidine or hydrochloric acid.

Demand growth is likely to track the following indicators:

Demand driver	Effect on histidine hydrochloride monohydrate
Growth in monoclonal antibodies	Increases formulation-development and commercial demand
Expansion of subcutaneous biologics	Supports use in concentrated formulations where pH control is critical
Peptide and protein drug approvals	Expands the number of injectable formulations requiring amino-acid buffers
Vaccine and recombinant-protein manufacturing	Creates recurring demand for GMP-grade material
Lyophilized biologics	Supports use in reconstitution and stability-focused formulations
Biosimilar launches	Can increase volume even when pricing falls
Small-molecule substitution	Limits growth where citrate, acetate, phosphate, or other buffers perform adequately

What is driving demand for histidine hydrochloride monohydrate?

Biologics remain the central demand engine. Protein products are sensitive to pH, ionic strength, aggregation, oxidation, deamidation, and surface interactions. Histidine buffers are frequently evaluated during formulation screening because they can support protein stability without the same precipitation or ionic-strength profile associated with some inorganic buffers.

High-concentration subcutaneous biologics

Subcutaneous delivery creates formulation constraints that are less significant in dilute intravenous products. Developers must manage injection volume, viscosity, protein concentration, local tolerability, and storage stability. Histidine-based systems may be selected when they support a concentrated formulation at an acceptable pH and osmolality.

The commercial impact is indirect. A successful subcutaneous formulation can generate long-term excipient demand across clinical batches, registration batches, and commercial production. However, the quantity of histidine hydrochloride per dose remains small relative to the value of the finished biologic.

Biosimilars and lifecycle reformulation

Biosimilar developers often reproduce the reference product’s formulation or develop a comparable formulation with different excipients. Histidine hydrochloride monohydrate can benefit from both approaches:

• Reference-product matching can create demand when the originator uses a histidine buffer.
• New delivery systems can create demand when developers optimize concentration, injection volume, or shelf life.
• Manufacturing changes may require new supplier qualification and analytical comparability work.

Biosimilar competition can increase excipient volume while reducing finished-drug prices. That makes volume growth more important than pricing expansion.

Peptides, vaccines, and advanced biologics

Peptide medicines, recombinant proteins, viral-vector products, and some vaccine formulations add demand diversity. These products do not all use histidine buffers, but they expand the formulation pipeline in which histidine hydrochloride is screened.

The strongest demand is likely to come from injectable products with demanding stability requirements. Oral dosage forms and conventional small-molecule tablets have limited relevance.

How does histidine hydrochloride monohydrate compare with competing buffers?

Histidine hydrochloride competes with other pharmaceutical buffers at the formulation-development stage. The relevant competition is technical, not only price-based.

Buffer system	Potential advantages	Commercial limitations
Histidine/histidine hydrochloride	Commonly evaluated for protein stability; suitable for mildly acidic formulations	May require careful control of salt form, pH, and raw-material quality
Phosphate	Established, widely available, inexpensive	Can affect ionic strength and may present compatibility concerns in some formulations
Citrate	Broad use and established supply	May affect tolerability or protein stability in certain products
Acetate	Useful in selected pH ranges; widely available	May be less suitable for some proteins or administration routes
Succinate	Used in selected biologic formulations	Smaller demand base than phosphate or citrate
Tris	Strong buffering capacity near neutral pH	Temperature-dependent pH and product-specific compatibility issues
Glycine	Can provide buffering and tonicity effects	May not provide the desired stability profile for every protein

No single buffer dominates all biologic formulations. Switching costs arise from formulation studies, analytical comparability, stability programs, regulatory documentation, and manufacturing validation. Those costs support incumbent excipient use once a product is commercialized.

Who supplies pharmaceutical-grade histidine hydrochloride monohydrate?

The supply base includes large pharmaceutical raw-material companies, amino-acid manufacturers, specialty excipient suppliers, and qualified regional producers. Commercial availability varies by grade, compendial status, packaging, batch size, and regulatory documentation.

Potential supplier categories include:

• Large life-science and pharmaceutical-material companies with GMP excipient portfolios.
• Amino-acid manufacturers using fermentation and downstream purification.
• Specialty chemical suppliers offering compendial or high-purity grades.
• Regional producers serving China, India, Europe, North America, and other regulated markets.
• Custom-manufacturing organizations able to provide dedicated or customer-specific supply arrangements.

Purchasers typically qualify suppliers using:

• Certificate of analysis consistency.
• USP-NF, Ph. Eur., JP, or other applicable compendial conformity.
• Residual solvent and elemental-impurity controls.
• Endotoxin, microbial, and bioburden data.
• Change-control procedures.
• Audit history and GMP systems.
• Dual-sourcing capability.
• Packaging and transport controls.
• Regulatory-support documentation.

The main barrier to entry is not chemical complexity alone. It is the ability to produce reproducible, low-bioburden, traceable material and maintain a regulatory-quality supply chain over the product lifecycle.

What is the FDA regulatory status of histidine hydrochloride monohydrate?

Histidine hydrochloride monohydrate is not a drug with independent FDA approval, marketing exclusivity, or therapeutic labeling. Its regulatory status is assessed within the finished pharmaceutical product.

The FDA’s Inactive Ingredient Database is the principal public reference for excipient precedent in approved drug products. Inclusion in the database can support formulation development, but it does not constitute blanket approval for every route, concentration, dosage form, or patient population. FDA review remains product-specific. [1]

Relevant regulatory considerations include:

• Identity and assay of the specific salt form.
• Water content and hydrate state.
• pH and solution characteristics.
• Bioburden and endotoxin control for parenteral use.
• Elemental impurities under ICH Q3D.
• Nitrosamine and impurity-risk assessments where applicable.
• Extractables and leachables compatibility.
• Supplier change control.
• Manufacturing-site and batch-traceability documentation.

The European Medicines Agency’s excipient guidance similarly places emphasis on excipient risk assessment, quality, functionality, and control within the medicinal product dossier. [2]

What patents protect histidine hydrochloride monohydrate?

The molecule and basic salt form are old chemical entities and are unlikely to support meaningful new composition-of-matter exclusivity in ordinary pharmaceutical use. The commercial protection is generally associated with the finished formulation, manufacturing process, delivery system, or specific therapeutic use.

IP category	Relevance to histidine hydrochloride monohydrate
Composition-of-matter patent on the basic compound	Generally weak or unavailable because of the age of the chemistry
Manufacturing-process patent	Possible for purification, crystallization, particle-size control, or impurity reduction
Formulation patent	Potentially material when histidine is combined with a biologic and defined concentration or pH
Method-of-use patent	Protects treatment of a disease, not the excipient as an independent product
Device or delivery patent	May cover autoinjectors, prefilled syringes, or subcutaneous administration
Trade secret	Relevant to fermentation, purification, crystallization, and quality-control methods

There is no Orange Book listing for histidine hydrochloride monohydrate as an excipient. It has no independent five-year new chemical entity exclusivity, three-year clinical-investigation exclusivity, or pediatric exclusivity. Paragraph IV litigation does not apply to the excipient as a standalone product.

Formulation patents may still affect a supplier or finished-drug manufacturer. A patent could claim a protein composition containing histidine or histidine hydrochloride within a defined pH, concentration, stabilizer combination, or storage condition. Such patents generally create risk for the finished product, not for the routine sale of the excipient into unrelated formulations.

When does histidine hydrochloride monohydrate lose exclusivity?

Histidine hydrochloride monohydrate has no standard pharmaceutical exclusivity expiration date because it is not marketed as an independently protected drug. Generic-entry timing is therefore determined by the finished drug’s patent and regulatory protections.

For a biologic using histidine hydrochloride monohydrate:

• Small-molecule ANDA and Paragraph IV frameworks generally do not govern the biologic itself.
• Biosimilar applicants may challenge patents covering the reference product’s formulation, use, manufacturing process, or delivery system.
• Formulation patents may expire after the relevant patent term, generally calculated from the earliest effective nonprovisional filing date under U.S. law, subject to patent-term adjustment or patent-term extension rules.
• A biosimilar may avoid a formulation patent through a different buffer, concentration, dosage form, or administration route.

The excipient’s availability does not determine biosimilar launch timing. The controlling issues are the biologic reference product’s exclusivity, patent estate, interchangeability strategy, and litigation outcome. [3]

What patent litigation and settlement risks affect the market?

No standalone Paragraph IV or Orange Book litigation is expected to target histidine hydrochloride monohydrate as an excipient. Litigation risk is concentrated in finished biologic products.

Relevant disputes may involve:

• A formulation containing histidine or histidine hydrochloride.
• A specific protein concentration and pH range.
• A stabilizer combination involving sugars or surfactants.
• Lyophilization parameters.
• Subcutaneous delivery.
• Manufacturing or purification methods.
• Biosimilar substitution and interchangeability.

Settlement agreements can delay biosimilar entry while allowing an applicant to launch before all asserted patents expire. The commercial effect on histidine demand depends on whether the biosimilar retains the reference formulation. A reformulated biosimilar may reduce demand for histidine even if it enters the market earlier.

What is the financial trajectory for histidine hydrochloride monohydrate?

The expected financial trajectory is positive in volume, moderate in value, and constrained in margin expansion.

Period	Expected market condition	Financial implication
Near term	Continued biologics development and commercial production	Stable-to-growing demand for qualified material
Medium term	More subcutaneous biologics, peptides, and biosimilars	Volume expansion and broader customer base
Longer term	Greater formulation standardization and buffer substitution	Volume remains resilient, but pricing power is limited

Revenue growth should come from:

• More commercial biologic products.
• Larger biologics manufacturing batches.
• Increased biosimilar production.
• Additional clinical programs using histidine-based buffers.
• Regional supply diversification.
• Demand for higher-documentation GMP grades.

Margin pressure may come from:

• Competition among amino-acid suppliers.
• Qualification of lower-cost Asian producers.
• Customer dual-sourcing programs.
• Substitution with citrate, phosphate, acetate, or other buffers.
• Low material consumption per finished dose.
• Procurement pressure from large contract manufacturers and biologic companies.

A supplier with validated pharmaceutical-grade capacity, compendial coverage, low impurity levels, and reliable regulatory support should command better retention than a supplier competing only on price. The strongest commercial position is likely in products qualified for sterile or parenteral applications, even where the material itself is supplied nonsterile.

What geographic markets offer the strongest growth?

North America and Europe remain high-value markets because biologic manufacturing and regulatory documentation requirements are extensive. China and India are important growth markets due to expanding biologics production, biosimilar development, vaccine manufacturing, and domestic pharmaceutical supply chains.

Region	Market characteristics
United States	High-value biologics, strict supplier qualification, strong demand for regulatory documentation
Europe	Established biologics manufacturing, compendial expectations, emphasis on excipient risk assessment
China	Expanding biologics and vaccine capacity; strong regional supplier competition
India	Growing biosimilar and injectable manufacturing base; cost-sensitive procurement
Japan and South Korea	Advanced biologics and high-quality pharmaceutical manufacturing
Latin America and other emerging markets	Smaller direct demand, supplied through regional distributors and global manufacturers

Geographic diversification is commercially important because pharmaceutical customers increasingly evaluate supply continuity, alternate manufacturing sites, and geopolitical exposure.

How strong is the commercial position of histidine hydrochloride monohydrate?

The excipient has moderate demand resilience but limited standalone pricing power.

Its strengths are:

• Established use in protein formulation development.
• Linkage to growing injectable biologics markets.
• Qualification and switching costs after commercial approval.
• Recurring demand through the product lifecycle.
• Potential use across multiple therapeutic classes.

Its weaknesses are:

• Substitution by other buffer systems.
• Small quantity per dose.
• Limited public market transparency.
• Dependence on the success of biologic products.
• Exposure to procurement consolidation.
• Limited standalone patent protection.

The strongest investment case is not a pure-play thesis on histidine hydrochloride monohydrate. It is a broader pharmaceutical-excipients or amino-acid manufacturing thesis supported by biologics growth, GMP capacity, multiple qualified customers, and a diversified product portfolio.

Key Takeaways

• Histidine hydrochloride monohydrate is a specialty pharmaceutical excipient used mainly for pH control in biologics and injectable formulations.
• Public sources do not establish a reliable standalone global market-revenue figure.
• Demand is linked primarily to monoclonal antibodies, peptides, vaccines, recombinant proteins, and high-concentration subcutaneous products.
• The excipient has no independent Orange Book exclusivity, FDA drug exclusivity, or Paragraph IV litigation pathway.
• Finished-product formulation patents can create indirect commercial risk when they claim histidine-containing biologic formulations.
• Volume growth is likely to outpace pricing growth because the material faces substitution and procurement pressure.
• Supplier qualification, GMP controls, impurity management, documentation, and supply continuity are more important than basic chemical availability.
• Geographic growth is strongest across North American, European, Chinese, Indian, Japanese, and South Korean biologics markets.
• The commercial opportunity is stronger for diversified pharmaceutical-material suppliers than for a single-product producer.

FAQs About Histidine Hydrochloride Monohydrate

Is histidine hydrochloride monohydrate the same as L-histidine?

No. L-histidine is the free amino acid, while histidine hydrochloride monohydrate is its hydrochloride salt with one molecule of crystallization water. The two materials have different molecular weights, specifications, and formulation effects.

Is histidine hydrochloride monohydrate used in monoclonal antibodies?

Yes. It is commonly evaluated and used as a buffer component in monoclonal-antibody formulations, subject to product-specific stability and compatibility results.

Can histidine hydrochloride monohydrate be replaced by phosphate buffer?

Sometimes. Replacement requires reformulation studies because buffer identity can affect protein aggregation, degradation, viscosity, osmolality, injection tolerability, and storage stability.

Is histidine hydrochloride monohydrate suitable for injectable drugs?

Pharmaceutical-grade material can be used in injectable products when it meets the finished-product specification and the manufacturer controls endotoxins, bioburden, impurities, and other applicable quality attributes.

Does histidine hydrochloride monohydrate have a drug master file?

Some manufacturers may maintain regulatory files or confidential quality documentation for their products, but a drug master file is supplier-specific and should not be inferred solely from the chemical identity or excipient use.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. European Medicines Agency. (2016). Guideline on the assessment of the quality of excipients in medicinal products for human use. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-assessment-quality-excipients-medicinal-products-human-use-first-version_en.pdf

3. U.S. Food and Drug Administration. (2020). Reference product exclusivity for biological products filed under section 351(a) of the PHS Act. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reference-product-exclusivity-biological-products-filed-under-section-351a-public-health-service-act